{"id":"W2910326971","doi":"10.1182/blood-2018-99-118577","title":"PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Medicine; Tolerability; Azacitidine; Internal medicine; Oncology; Cohort; Adverse effect; Cancer; Pembrolizumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002739658,0.0005462582,0.001158691,0.0002784403,0.000198088,0.0007402851,0.0003981311,0.0006152455,0.001548891],"category_scores_gemma":[0.001610426,0.00022007,0.001390648,0.0002527314,0.0003951702,0.0004746222,0.0002396233,0.001596928,0.0002384773],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006443853,"about_ca_system_score_gemma":0.0006492526,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003362487,"about_ca_topic_score_gemma":0.0007529875,"domain_scores_codex":[0.9993854,0.0003491149,0.00005357574,0.00007386368,0.000082456,0.00005555026],"domain_scores_gemma":[0.9982664,0.0006888424,0.0004413526,0.0001388729,0.0001597131,0.0003048888],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5916814,0.02382272,0.07075531,0.001795218,0.004927106,0.0005427585,0.0003282831,0.007428501,0.07801542,0.0003599191,0.002735326,0.217608],"study_design_scores_gemma":[0.1385749,0.7044518,0.1237982,0.0001739559,0.003880012,0.001095067,0.0001064536,0.005398441,0.01726166,0.0002732852,0.004931434,0.00005486887],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995452,0.002251849,0.0004061639,0.0001317819,0.00001388256,0.0003383614,0.0006438417,0.00001784508,0.0007444439],"genre_scores_gemma":[0.9971817,0.0007787472,0.0003714577,0.0001452936,0.00004217402,0.000193703,0.0009204676,0.000005211813,0.0003612008],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002739658,"threshold_uncertainty_score":0.01448882,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01759514171835927,"score_gpt":0.2900716015480648,"score_spread":0.2724764598297056,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}